Accordingly, we found that EphA2-KO BxPC3 pancreatic cancer cells presented reduced migratory properties that are comparable to WT-cells treated with either ephrinA1-Fc or our dimeric agonistic agents. This evidence concerns the gene EPHA2 and pancreatic neoplasm.